Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 11th Preview)
-
AI in protein design and safer lab use
A new report focuses on making protein language models (pLMs) safer and more transparent as they become embedded in protein design workflows. The piece outlines how current pLM capabilities—sequence prediction and design—still leave gaps around interpretability and verification, prompting calls for clearer model behavior and lab-facing controls.
-
Roche deal for AI digital pathology
Roche announced it will acquire PathAI for $750 million upfront, aiming to expand AI-powered capabilities in digital pathology workflows. The deal targets PathAI’s technology used by pathology laboratories and biopharma teams, positioning Roche to integrate machine-learning tools closer to routine diagnostic decision-making and translational development.
-
Clinical update in oncology gene therapy
enGene’s shares plunged after updated Phase II LEGEND trial data for its nonviral gene therapy candidate, detalimogene (formerly EG-70), in high-risk BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ (CIS±papillary). The updated readout showed complete response durability falling from earlier results, including a six-month CR drop versus the company’s prior cohort.
-
Asset-backed CF funding for Anagram
Blackstone Life Sciences committed $250 million to Anagram Therapeutics, backing the company’s oral enzyme replacement therapy program for patients with exocrine pancreatic insufficiency. The funding underscores investor appetite for oral and potentially more scalable enzyme approaches in cystic fibrosis-adjacent care and rare-disease billing realities where access and administration can be limiting.
-
Windward Bio raises for respiratory biologics
Windward Bio secured $165 million to advance long-acting antibody programs across asthma and COPD, with additional development planned for respiratory and dermatological indications. The financing is designed to support clinical trials as the company targets dosing advantages over existing biologics, aiming to convert pipeline momentum into near-term trial progress.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.